Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

RBC alloantibody prevalence and specificity in a Western Norwegian tertiary hospital.

Erikstein BS, Hagen KG, Hervig T.

Transfus Med. 2019 Jun;29(3):169-178. doi: 10.1111/tme.12511. Epub 2018 Jan 29.

PMID:
29377396
2.

Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.

Andresen V, Erikstein BS, Mukherjee H, Sulen A, Popa M, Sørnes S, Reikvam H, Chan KP, Hovland R, McCormack E, Bruserud Ø, Myers AG, Gjertsen BT.

Cell Death Dis. 2016 Dec 1;7(12):e2497. doi: 10.1038/cddis.2016.392.

3.

Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine.

Bredholt T, Ersvær E, Erikstein BS, Sulen A, Reikvam H, Aarstad HJ, Johannessen AC, Vintermyr OK, Bruserud Ø, Gjertsen BT.

BMC Pharmacol Toxicol. 2013 Jul 11;14:35. doi: 10.1186/2050-6511-14-35.

4.

Flotillins as regulators of ErbB2 levels in breast cancer.

Pust S, Klokk TI, Musa N, Jenstad M, Risberg B, Erikstein B, Tcatchoff L, Liestøl K, Danielsen HE, van Deurs B, Sandvig K.

Oncogene. 2013 Jul 18;32(29):3443-51. doi: 10.1038/onc.2012.357. Epub 2012 Aug 6.

PMID:
22869152
5.

Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment.

Erikstein BS, Hagland HR, Nikolaisen J, Kulawiec M, Singh KK, Gjertsen BT, Tronstad KJ.

J Cell Biochem. 2010 Oct 15;111(3):574-84. doi: 10.1002/jcb.22741.

6.

Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB.

Erikstein BS, McCormack E, Tronstad KJ, Schwede F, Berge R, Gjertsen BT.

Leuk Res. 2010 Jan;34(1):77-84. doi: 10.1016/j.leukres.2009.09.005. Epub 2009 Sep 27.

PMID:
19786302
7.

Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy.

Edvardsen H, Kristensen VN, Grenaker Alnaes GI, Bøhn M, Erikstein B, Helland A, Børresen-Dale AL, Fosså SD.

Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1163-71.

PMID:
17336217
8.

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.

Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Bergh J.

Ann Oncol. 2007 Apr;18(4):694-700. Epub 2007 Feb 13.

PMID:
17301072
9.

Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.

Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Bergh J, Isola J.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185-91.

10.

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.

J Clin Oncol. 2006 Jun 1;24(16):2428-36. Epub 2006 May 8.

PMID:
16682728
11.

Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy.

Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G.

Int J Cancer. 2006 Jun 1;118(11):2877-81.

12.

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G.

J Clin Oncol. 2005 Aug 1;23(22):5126-37. Epub 2005 Jun 27.

PMID:
15983390
13.

Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.

Robertson JF, Erikstein B, Osborne KC, Pippen J, Come SE, Parker LM, Gertler S, Harrison MP, Clarke DA.

Clin Pharmacokinet. 2004;43(8):529-38.

PMID:
15170367
14.
15.

Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study.

Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fosså SD.

Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1397-404.

PMID:
12873686
16.

Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study.

Söreide JA, Varhaug JE, Fjösne HE, Erikstein B, Jacobsen AB, Skovlund E, Kvinnsland S.

Eur J Surg Oncol. 2002 Aug;28(5):505-10.

PMID:
12217302
17.

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.

Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C.

J Clin Oncol. 2002 Aug 15;20(16):3396-403.

PMID:
12177099
18.

The potential for aromatase inhibition in breast cancer prevention.

Lønning PE, Kragh LE, Erikstein B, Hagen A, Risberg T, Schlichting E, Geisler J.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4423s-4428s; discussion 4411s-4412s. Review.

PMID:
11916235
19.

Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients.

Hall KS, Wiklund T, Erikstein B, Holte H, Kvalheim G, Sommer HH, Andersen A, Skovlund E, Bergh J, Hall C.

Breast Cancer Res Treat. 2001 Jun;67(3):235-44.

PMID:
11561769
20.

Genetic susceptibility and environmental estrogen-like compounds.

Kristensen VN, Kure EH, Erikstein B, Harada N, Børresen-Dale A.

Mutat Res. 2001 Oct 1;482(1-2):77-82. Review.

PMID:
11535251
21.

Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival.

Jain AN, Chin K, Børresen-Dale AL, Erikstein BK, Eynstein Lonning P, Kaaresen R, Gray JW.

Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7952-7.

22.

Elevated CA125 in breast cancer--A sign of advanced disease.

Norum LF, Erikstein B, Nustad K.

Tumour Biol. 2001 Jul-Aug;22(4):223-8.

PMID:
11399947
23.

Screening breast cancer patients for Norwegian ATM mutations.

Laake K, Vu P, Andersen TI, Erikstein B, Kåresen R, Lonning PE, Skovlund E, Børresen-Dale AL.

Br J Cancer. 2000 Dec;83(12):1650-3.

24.

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N.

Lancet. 2000 Oct 21;356(9239):1384-91. Erratum in: Lancet 2000 Dec 23-30;356(9248):2196.

PMID:
11052580
25.

Genetic variants of CYP19 (aromatase) and breast cancer risk.

Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Kåresen R, Kristensen T, Børresen-Dale AL.

Oncogene. 2000 Mar 2;19(10):1329-33.

26.

Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis.

Naderi S, Blomhoff R, Myklebust J, Smeland EB, Erikstein B, Norum KR, Blomhoff HK.

Exp Cell Res. 1999 Oct 10;252(1):144-53.

PMID:
10502407
27.

CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1.

Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lønning PE, Erikstein B, Kåresen R, Gabrielsen OS, Børresen-Dale AL.

Cancer Res. 1999 Jun 15;59(12):2825-8.

29.

Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients.

Nedelcheva Kristensen V, Andersen TI, Erikstein B, Geitvik G, Skovlund E, Nesland JM, Børresen-Dale AL.

Pharmacogenetics. 1998 Oct;8(5):441-7. Erratum in: Pharmacogenetics 1999 Feb;9(1):following 127.

PMID:
9825836
30.

Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.

Bergh J, Wiklund T, Erikstein B, Fornander T, Bengtsson NO, Malmström P, Kellokumpu-Lehtinen P, Anker G, Bennmarker H, Wilking N.

Ann Oncol. 1998 Apr;9(4):403-11.

PMID:
9636831
31.

A rare CYP19 (aromatase) variant may increase the risk of breast cancer.

Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Børresen-Dale AL.

Pharmacogenetics. 1998 Feb;8(1):43-8.

PMID:
9511180
32.

Expression of stromelysin-3 in medullary carcinoma of the breast.

Holm R, Flørenes VA, Erikstein B, Nesland JM.

Anticancer Res. 1997 Sep-Oct;17(5B):3725-7.

PMID:
9427769
33.

[High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood].

Kolstad A, Holte H, Kvaløy S, Jakobsen E, Erikstein B, Aurlien E, Kvalheim G, Bøhler PJ, Langholm R.

Tidsskr Nor Laegeforen. 1996 Sep 10;116(21):2547-51. Norwegian.

PMID:
8928122
34.

[High-dose therapy of cancer with CD34 positive cells as stem cell support].

Kvalheim G, Pharo A, Holte H, Jakobsen E, Erikstein B, Kvaløy S, Beiske K, Nesland JM, Smeland EB.

Tidsskr Nor Laegeforen. 1996 Sep 10;116(21):2542-6. Norwegian.

PMID:
8928121
35.

[Tamoxifen--effects and side-effects].

Erikstein BK.

Tidsskr Nor Laegeforen. 1996 Jun 20;116(16):1872. Norwegian. No abstract available.

PMID:
8711696
36.

Regulation of growth in a neoplastic B cell line by transfected subunits of 3',5'-cyclic adenosine monophosphate-dependent protein kinase.

Taskén K, Andersson KB, Erikstein BK, Hansson V, Jahnsen T, Blomhoff HK.

Endocrinology. 1994 Nov;135(5):2109-19.

PMID:
7956934
37.

Flow cytometric investigation of a possible precursor--product relationship between oval cells and parenchymal cells in the rat liver.

Gerlyng P, Grotmol T, Stokke T, Erikstein B, Seglen PO.

Carcinogenesis. 1994 Jan;15(1):53-9.

PMID:
8293549
38.

Binucleation and polyploidization patterns in developmental and regenerative rat liver growth.

Gerlyng P, Abyholm A, Grotmol T, Erikstein B, Huitfeldt HS, Stokke T, Seglen PO.

Cell Prolif. 1993 Nov;26(6):557-65.

PMID:
9116122
39.

CDw75 antigen expression in breast lesions.

Reed W, Erikstein BK, Funderud S, Lilleng R, Tvedt K, Nesland JM.

Pathol Res Pract. 1993 May;189(4):394-8.

PMID:
7688897
40.

Expression of CD18 (integrin beta 2 chain) correlates with prognosis in malignant B cell lymphomas.

Erikstein BK, Holte H, Kvaløy S, Andersson KB, Steen HB, Hannisdal E, Smeland EB.

Br J Haematol. 1993 Mar;83(3):392-8.

PMID:
8097923
41.

The retinoblastoma gene product is bound in the nucleus in early G1 phase.

Stokke T, Erikstein BK, Smedshammer L, Boye E, Steen HB.

Exp Cell Res. 1993 Jan;204(1):147-55.

PMID:
8416792
42.

Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B cells.

Blomhoff HK, Smeland EB, Erikstein B, Rasmussen AM, Skrede B, Skjønsberg C, Blomhoff R.

J Biol Chem. 1992 Nov 25;267(33):23988-92.

43.

Reduced proliferative activity of polyploid cells in primary hepatocellular carcinoma.

Gerlyng P, Grotmol T, Erikstein B, Stokke T, Seglen PO.

Carcinogenesis. 1992 Oct;13(10):1795-801.

PMID:
1330342
44.

Cell cycle-dependent regulation of CDw75 (beta-galactoside alpha-2,6-sialyltransferase) on human B lymphocytes.

Erikstein BK, Funderud S, Beiske K, Aas-Eng A, De Lange Davies C, Blomhoff HK, Smeland EB.

Eur J Immunol. 1992 May;22(5):1149-55.

PMID:
1577059
45.

A new method for detachment of Dynabeads from positively selected B lymphocytes.

Rasmussen AM, Smeland EB, Erikstein BK, Caignault L, Funderud S.

J Immunol Methods. 1992 Feb 5;146(2):195-202.

PMID:
1371532
46.

Interleukin-7 differentiates a subgroup of acute lymphoblastic leukemias.

Skjønsberg C, Erikstein BK, Smeland EB, Lie SO, Funderud S, Beiske K, Blomhoff HK.

Blood. 1991 Jun 1;77(11):2445-50.

PMID:
2039826
47.

Cell cycle-specific expression and nuclear binding of DNA polymerase alpha.

Stokke T, Erikstein B, Holte H, Funderud S, Steen HB.

Mol Cell Biol. 1991 Jun;11(6):3384-9.

48.

Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes.

Erikstein BK, Smeland EB, Blomhoff HK, Funderud S, Prydz K, Lesslauer W, Espevik T.

Eur J Immunol. 1991 Apr;21(4):1033-7.

PMID:
1850359
49.

Use of size fractionation of in vitro-activated human B lymphocytes for studies of cell cycle-dependent growth regulation.

Erikstein BK, Schwarze P, Blomhoff HK, Funderud S, Stokke T, Smeland EB.

Scand J Immunol. 1991 Jan;33(1):51-60.

PMID:
1899949
50.

Simultaneous assessment of chromatin structure, DNA content, and antigen expression by dual wavelength excitation flow cytometry.

Stokke T, Holte H, Erikstein B, Davies CL, Funderud S, Steen HB.

Cytometry. 1991;12(2):172-8.

Supplemental Content

Loading ...
Support Center